Lysosome dysfunction arises early and propels Alzheimer's disease (AD). Herein, we show
that amyloid precursor protein (APP), linked to early-onset AD in Down syndrome (DS), acts …

Aducanumab, co-developed by Eisai (Japan) and Biogen (US), has received Food and Drug
Administration approval for treating Alzheimer's disease (AD). In addition, its successor …

After several years of research in the field of Alzheimer's disease (AD), it is still unclear how
amyloid-beta (Aβ) and Tau, two key hallmarks of the disease, mediate the neuropathogenic …

Amyloid-β peptides (Aβs) are produced via cleavage of the transmembrane region of the
amyloid precursor protein (APP) by γ-secretase and are responsible for Alzheimer's disease …

Background: In the past 10 years, significant progress has been made in understanding the
pathogenic chain of events that causes Alzheimer's disease (AD). According to the most …

Diagnosis of Alzheimer's disease (AD) is crucial especially for the complete comprehension
of pathology and clinical therapy of the disorder, as well as in declining the severity of the …

Spatial navigation and path integration impairments are sensitive markers of pathological
decline during the early stages of Alzheimer's disease (AD). To investigate the neural circuit …

During the past two decades, cerebrospinal fluid (CSF) and blood biomarkers that reflect the
neuropathological hallmarks of Αlzheimer's disease (ΑD), including deposition of …

Neurodegenerative diseases, such as Alzheimer's disease, result in severe cognitive
decline and memory impairment, which negatively affects both patient and caregiver quality …

Alzheimer's disease (AD) has grown to a global health crisis which comes with an urgent
need for disease-modifying and preventative therapies. To advance current therapeutic …